Janssen Sciences Ireland UC

Politician(s) lobbied: Deirdre Gillane (Chief of Staff), Department of the Taoiseach; Jim O'Callaghan (Minister), Department of Justice

Intent: To highlight the contribution of J&J to the Irish economy::To seek meetings between senior J&J leaders and Government

Methods: EmailMeeting

Politician(s) lobbied: Cáit Moran (Deputy Permanent Representative of Ireland to the European Union), Department of Foreign Affairs

Intent: To ensure J&J alignment and support for Ireland's EU Presidency objectives in H2 2026::To discuss the possibility of an official visit to J&J sites during the Presidency

Methods: Meeting

Politician(s) lobbied: Cáit Moran (Deputy Permanent Representative of Ireland to the European Union), Department of Foreign Affairs

Intent: To highlight concerns about the feasibility of plans for implementation of medicine Shortage Prevention Plans::To encourage the giving of consideration of an extended deadline for implementation of SPPs and for revision of the scope in favour of a phased or risk-based approach

Methods: Meeting

Politician(s) lobbied: Micheál Martin (An Taoiseach), Department of the Taoiseach

Intent: To highlight the positive economic and social impact of Johnson & Johnson's presence in Ireland and encourage the maintenance of a positive relationship.

Methods: Informal communication

Politician(s) lobbied: Teresa Costello (Senator), Seanad

Intent: To discuss the challenge of delayed patient access to new medicines and highlight the potential for the new IPHA Framework Agreement to improve access to innovation if implemented::To highlight the potential value of the national strategy for the life sciences and promote integration of patient access objectives

Methods: EmailMeeting

Politician(s) lobbied: Niall Redmond (Assistant Secretary), Department of Health; Derek Tierney (Assistant Secretary), Department of Health; Professor Mary Horgan (Chief Medical Officer), Department of Health

Intent: To welcome and highlight the value of the new IPHA Framework Agreement on Pricing & Supply of Medicines and its potential to improve access to innovation for patients::To encourage collaborative implementation of the Framework Agreement in the coming months and years

Methods: Meeting

Politician(s) lobbied: Verona Murphy (TD), Dáil Éireann, the Oireachtas; Helen McEntee (Minister), Department of Foreign Affairs; Peter Burke (Minister), Department of Enterprise, Trade and Employment; Conor Glynn (Special Adviser), Department of Foreign Affairs; Micheál Martin (Taoiseach), Dáil Éireann, the Oireachtas; Jack Chambers (Minister), Department of Public Expenditure, NDP Delivery and Reform; Maeve von Heynitz (Director General), Department of Foreign Affairs

Intent: To highlight the importance of the new IPHA Framework Agreement on the Supply and Pricing of Medicines and to encourage its implementation by the State in the coming years::To highlight the challenge of delayed patient access to innovative medicines and the potential for improvement through reform and resourcing of the reimbursement system::To welcome progress towards a new national life sciences strategy::To encourage a pro-innovation position on any policy files relevant to the life sciences sector by Ireland during its Presidency of the European Union in H2 2026

Methods: Meeting

Politician(s) lobbied: John Newham (Assistant Secretary), Department of Enterprise, Trade and Employment; Muiris O’Connor (Assistant Secretary), Department of Health

Intent: To promote the development and timely adoption of a holistic national life sciences policy joining relevant aspects of health and economic policy::To ensure policy coordination by achieving alignment of the life sciences strategy with other government policies, including in the areas of medicines access, reimbursement system reform, and promotion of clinical research, as well as alignment with government positions on EU policy files.

Methods: Informal communication

Politician(s) lobbied: Billy Kelleher (MEP), European Parliament; Regina Doherty (MEP), European Parliament; Seán Kelly (MEP), European Parliament

Intent: To encourage the prioritisation of progress on Biotech Act I before and during the Irish Presidency of the European Union::To support and refine Commission proposals for an effective SPC extension to stimulate new drug discovery and development::To support and develop Commission proposals for amendments to the Clinical Trials Regulation in the Biotech Act

Methods: Informal communicationMeeting

Politician(s) lobbied: Barry Andrews (MEP), European Parliament; Billy Kelleher (MEP), European Parliament

Intent: To inform MEPs about recent developments in TPLF in Europe and highlight the risks to consumers, businesses, and competitiveness of unregulated third-party litigation funding in the EU.

Methods: Meeting